Post-exposure treatment of Ebola virus using passive immunotherapy: proposal for a new strategy
AffiliationUMR 216, Mother and Child Facing Tropical Disease, Research Institute for Development (IRD), Cotonou, Benin, and School of Pharmacy, Paris Descartes University
Venom Immunochemistry, Pharmacology and Emergency Response (VIPER) Institue, University of Arizona
Institute of Biotechnology, National Autonomous University of Mexico (UNAM)
Institut de Recherche pour le Développement (IRD)
MetadataShow full item record
CitationChippaux et al. Journal of Venomous Animals and Toxins including Tropical Diseases (2015) 21:3 DOI 10.1186/s40409-015-0003-1
Rights© 2015 Chippaux et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0).
Collection InformationThis item is part of the UA Faculty Publications collection. For more information this item or other items in the UA Campus Repository, contact the University of Arizona Libraries at email@example.com.
AbstractBACKGROUND: Better treatments are urgently needed for the management of Ebola virus epidemics in Equatorial Africa. METHODS: We conducted a systematic review of the literature on the use of passive immunotherapy for the treatment or prevention of Ebola virus disease. We placed findings from this review into the context of passive immunotherapy currently used for venom-induced disease, and recent improvements in manufacturing of polyvalent antivenom products. RESULTS: Passive immunotherapy appears to be one of the most promising specific treatments for Ebola. However, its potential has been incompletely evaluated, considering the overall experience and recent improvement of immunotherapy. Development and use of heterologous serum derivatives could protect people exposed to Ebola viruses with reasonable cost and logistics. CONCLUSION: Hyperimmune equine IgG fragments and purified polyclonal whole IgG deserve further consideration as treatment for exposure to the Ebola virus.
PubMed Central IDPMC4336475
VersionFinal published version
Except where otherwise noted, this item's license is described as © 2015 Chippaux et al.; licensee BioMed Central. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0).
- Equine-Origin Immunoglobulin Fragments Protect Nonhuman Primates from Ebola Virus Disease.
- Authors: Wang H, Wong G, Zhu W, He S, Zhao Y, Yan F, Rahim MN, Bi Y, Zhang Z, Cheng K, Jin H, Cao Z, Zheng X, Gai W, Bai J, Chen W, Zou Y, Gao Y, Gao GF, Yang S, Xia X, Qiu X
- Issue date: 2019 Mar 1
- Treatment of ebola virus disease.
- Authors: Kilgore PE, Grabenstein JD, Salim AM, Rybak M
- Issue date: 2015 Jan
- Successful post-exposure prophylaxis of Ebola infected non-human primates using Ebola glycoprotein-specific equine IgG.
- Authors: Pyankov OV, Setoh YX, Bodnev SA, Edmonds JH, Pyankova OG, Pyankov SA, Pali G, Belford S, Lu L, La M, Lovrecz G, Volchkova VA, Chappell KJ, Watterson D, Marsh G, Young PR, Agafonov AA, Farmer JF, Volchkov VE, Suhrbier A, Khromykh AA
- Issue date: 2017 Feb 3
- Ebola exposure, illness experience, and Ebola antibody prevalence in international responders to the West African Ebola epidemic 2014-2016: A cross-sectional study.
- Authors: Houlihan CF, McGowan CR, Dicks S, Baguelin M, Moore DAJ, Mabey D, Roberts CH, Kumar A, Samuel D, Tedder R, Glynn JR
- Issue date: 2017 May
- Post-exposure prophylaxis against Ebola virus disease with experimental antiviral agents: a case-series of health-care workers.
- Authors: Jacobs M, Aarons E, Bhagani S, Buchanan R, Cropley I, Hopkins S, Lester R, Martin D, Marshall N, Mepham S, Warren S, Rodger A
- Issue date: 2015 Nov